桂龙咳喘宁品牌怎么样 申请店铺

我要投票 桂龙咳喘宁在医疗器械行业中的票数:489 更新时间:2025-09-03
桂龙咳喘宁是哪个国家的品牌?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力桂龙咳喘宁品牌出海!将品牌入驻外推网,定制桂龙咳喘宁品牌推广信息,可以显著提高桂龙咳喘宁产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

桂龙咳喘宁怎么样

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://brand.waitui.com/0d765d197.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

蔚来李斌:四季度目标是平均每个月5万台交付量

9月2日,蔚来创始人、董事长、CEO李斌在2025年二季度财报电话会上表示,今年四季度的目标是能做到平均每个月5万台的交付量,也就是说三个品牌的整个季度交付量总计能超过15万台。(第一财经)

4小时前

湖南:支持培育一批人工智能优势企业

36氪获悉,据长沙发布,9月2日,湖南省委书记沈晓明在长沙调研人工智能产业发展并主持召开座谈会。沈晓明指出,要进一步明确发展方向,充分发挥湖南特色和优势,大力推动人工智能与先进制造、文化、现代农业、医学等领域融合发展。要进一步明确发展重点,支持培育一批人工智能优势企业,前瞻布局未来应用场景,提升湖南人工智能领域的核心竞争力。要进一步明确发展目标,围绕人工智能基础研究、产业发展、应用场景培育、人才培养等方面细化目标任务和工作举措,确保人工智能安全、稳健、可持续发展。

4小时前

咖啡连锁品牌Black Rock拟赴美IPO,目标估值8.61亿美元

咖啡连锁品牌Black Rock Coffee Bar于周二表示,其计划在纽约首次公开募股(IPO)中寻求最高8.607亿美元的估值。这家总部位于亚利桑那州斯科茨代尔的公司计划发行1470万股股票,每股发行价区间为16美元至18美元,按此计算,募资额最高可达2.65亿美元。(新浪财经)

4小时前

*ST春天:不存在其他应披露而未披露的重大信息

36氪获悉,*ST春天公告,公司股票在2025年8月29日、9月1日、9月2日连续3个交易日内日收盘价格涨幅偏离值累计达到12%,属于股票交易异常波动。经自查及向控股股东、实际控制人发函核实,截至公告披露日,除已披露事项外,不存在其他应披露而未披露的重大事项。公司近期日常经营情况和外部环境较前期未发生重大变化,生产经营情况正常。控股股东及实际控制人确认除已披露信息外,不存在其他应披露而未披露的重大信息。

4小时前

华盛昌:“DeepSense深度感测大模型”备案通过

36氪获悉,华盛昌公告,近日,“DeepSense深度感测大模型”正式通过生成式人工智能服务备案。该大模型主要应用于仪器仪表、专业测量和检测等相关行业,为下游应用企业和专业人员提供智能化、高效化的专业技术支持和一体化解决方案。备案通过意味着公司在“AI+测量智能体”领域取得阶段性成果,可以为行业客户提供行业领先的测量类垂域大模型,更为下游客户提供“AI+传感器”的工业领域深度感测解决方案,助力工业和专业领域实现设备效能提升、生产流程闭环控制与数字化管理转型。

4小时前

本页详细列出关于桂龙咳喘宁的品牌信息,含品牌所属公司介绍,桂龙咳喘宁所处行业的品牌地位及优势。
咨询